A p38 MAPK-MEF2C pathway regulates B-cell proliferation

B lymphocytes are an integral part of the adaptive immune system. On antigen binding to the B-cell receptor (BCR), B cells rapidly proliferate and differentiate into antibody-secreting plasma cells. The p38 mitogen-activated protein kinase (MAPK) pathway functions downstream of the BCR to control cell proliferation, but the transcriptional effectors of this pathway in B cells have remained elusive. In the present study, we inactivated Mef2c exclusively in B cells by conditional gene targeting in mice. Loss of MEF2C function resulted in a reduced immune response to antigen, defective germinal center formation, and a severe defect in B-cell proliferation, and we show that MEF2C regulates proliferation in response to BCR stimulation via the p38 MAPK pathway. p38 directly phosphorylates MEF2C via three residues in the C-terminal transactivation domain, establishing MEF2C as a direct transcriptional effector of BCR signaling via p38 MAPK.

[1]  Michelle M. Sandau,et al.  Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation , 2008, Nature Immunology.

[2]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[3]  J. Cyster,et al.  Germinal-center organization and cellular dynamics. , 2007, Immunity.

[4]  S. Gerondakis,et al.  Regulating B‐cell activation and survival in response to TLR signals , 2007, Immunology and cell biology.

[5]  Y. J. Kang,et al.  The role of the p38 pathway in adaptive immunity. , 2007, Cellular & molecular immunology.

[6]  L. Genestier,et al.  TLR Agonists Selectively Promote Terminal Plasma Cell Differentiation of B Cell Subsets Specialized in Thymus-Independent Responses1 , 2007, The Journal of Immunology.

[7]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[8]  B. Black,et al.  The transcription factor MEF2C is required for craniofacial development. , 2007, Developmental cell.

[9]  B. Huber,et al.  Molecular pathogenesis of chronic lymphocytic leukemia. , 2006, Current molecular medicine.

[10]  Olivier Pertz,et al.  Neutrophil polarization: spatiotemporal dynamics of RhoA activity support a self-organizing mechanism. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Copeland,et al.  Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.

[12]  John J. Andreucci,et al.  Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. , 2005, Developmental biology.

[13]  U. Siebenlist,et al.  Control of lymphocyte development by nuclear factor-κB , 2005, Nature Reviews Immunology.

[14]  Zhenguo Wu,et al.  Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.

[15]  T. Gulick,et al.  Phosphorylation and Alternative Pre-mRNA Splicing Converge To Regulate Myocyte Enhancer Factor 2C Activity , 2004, Molecular and Cellular Biology.

[16]  J. Kearney,et al.  Development and selection of marginal zone B cells , 2004, Immunological reviews.

[17]  M. Mårback,et al.  Phosphorylation Motifs Regulating the Stability and Function of Myocyte Enhancer Factor 2A* , 2003, The Journal of Biological Chemistry.

[18]  M. Cooper.  Exploring lymphocyte differentiation pathways , 2002, Immunological reviews.

[19]  David E. Misek,et al.  DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. , 2001, Human molecular genetics.

[20]  E. Olson,et al.  Control of muscle development by dueling HATs and HDACs. , 2001, Current opinion in genetics & development.

[21]  E. Miska,et al.  HDAC4 deacetylase associates with and represses the MEF2 transcription factor , 1999, The EMBO journal.

[22]  C. Drake,et al.  The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. , 1999, Developmental biology.

[23]  Andrew D. Sharrocks,et al.  Targeting of p38 Mitogen-Activated Protein Kinases to MEF2 Transcription Factors , 1999, Molecular and Cellular Biology.

[24]  G. Lyons,et al.  Requirement of the MADS-box transcription factor MEF2C for vascular development. , 1998, Development.

[25]  G. Lyons,et al.  Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. , 1998, Molecular immunology.

[26]  A. Strasser,et al.  B Lymphocytes Differentially Use the Rel and Nuclear Factor κB1 (NF-κB1) Transcription Factors to Regulate Cell Cycle Progression and Apoptosis in Quiescent and Mitogen-activated Cells , 1998, The Journal of experimental medicine.

[27]  C. Bucana,et al.  Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.

[28]  Jiahuai Han,et al.  Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation , 1997, Nature.

[29]  K. Rajewsky,et al.  B lymphocyte-specific, Cre-mediated mutagenesis in mice. , 1997, Nucleic acids research.

[30]  M. Gold,et al.  Signal Transduction by the B‐Cell Antigen Receptor , 1995, Annals of the New York Academy of Sciences.

[31]  Philip R. Cohen,et al.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1 , 1995, FEBS letters.

[32]  U. Siebenlist,et al.  Control of lymphocyte development by nuclear factor-kappaB. , 2005, Nature reviews. Immunology.

[33]  E. Olson,et al.  MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.

[34]  A. Rolink,et al.  B cell development and immunoglobulin gene transcription in the absence of Oct-2 and OBF-1 , 2001, Nature Immunology.

[35]  J. Molkentin,et al.  Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. , 2000, Trends in cardiovascular medicine.

[36]  B. Black,et al.  Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. , 1998, Annual review of cell and developmental biology.

[37]  A. DeFranco,et al.  Molecular aspects of B-lymphocyte activation. , 1987, Annual review of cell biology.

[38]  David D. McDonald,et al.  Programs , 1984, CL.